Prime Medicine Inc 2025年季度报告

FORM10-Q Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains express or implied statements which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”). All statements, other than statements of historical facts, contained in this Quarterly Report on Form10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management, are forward-looking statements, which are based on management’s belief andassumptions and on information currently available to our management. These statements involve substantial risks, assumptions anduncertainties. The words “anticipate,” “believe,” “envision,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “predict,” The forward-looking statements in this Quarterly Report on Form 10-Q include statements about: •the initiation, timing, progress and results of our research and development programs, product candidates, preclinical studiesand future clinical trials; •our ability to demonstrate, and the timing of, preclinical proof-of-conceptin vivofor multiple programs; •our ability to advance any current and future product candidates that we may identify and successfully complete any clinicalstudies, including the manufacture of any such product candidates; •our ability to pursue our areas of focus and any other additional programs we may advance; •our ability to quickly leverage programs within our initial target indications and to progress additional programs to furtherdevelop our pipeline; •the timing of our investigational new drug application (“IND”) submissions; •the ability of our Prime Editing technology to address unmet medical needs in patients; •the implementation of our strategic plans for our business, programs and technology; •the scope and duration of protection we are able to establish and maintain for intellectual property rights covering our PrimeEditing technology; •developments related to our competitors and our industry; •our ability to leverage the clinical, regulatory, and manufacturing advancements made by gene therapy and gene editingprograms to accelerate our clinical trials and approval of product candidates; •our ability to maintain collaborations or strategic relationships and the ability to identify and enter into future licenseagreements and collaborations; •developments related to our Prime Editing technology; •regulatory developments in the United States and foreign countries; •our ability to attract and retain key scientific and management personnel; •our estimates of our expenses, capital requirements, needs for additional financing; •the effect of unfavorable macroeconomic conditions or market volatility resulting from national or global economicconditionsor geopolitical developments,including rising inflation and capital market disruptions,changes in U.S. •our expectations regarding the anticipated timeline of our cash runway, future financial performance and our ability to •other risks and uncertainties, including those listed under the caption “Risk Factors.” We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and these statementsmay be affected by inaccurate assumptions or by known or unknown risks and uncertainties. You should not place undue reliance onour forward-looking statements. Actual results or events could differ materially from the plans, intenti